Monitor Closely (2)perphenazine, methylphenidate. Methylphenidate is contraindicated during treatment with an MAOI and also within a minimum of 14 days following discontinuation of an MAOI. Monitor BP. provider for the most current information. Applies only to oral form of both agents. Potential for additive CNS stimulation. Since the characteristics of methylphenidate extended release capsules (Ritalin LA) are pH dependent, coadministration of antacids or acid suppressants could alter the release of methylphenidate. Use Caution/Monitor. protriptyline, methylphenidate. Use Caution/Monitor. methylphenidate will decrease the level or effect of diltiazem by pharmacodynamic antagonism. Monitor Closely (1)methylphenidate and solriamfetol both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Monitor BP. Choose your patient's existing medication (e.g. Use Caution/Monitor. Monitor BP. Use Caution/Monitor. methylphenidate, epinephrine inhaled. Interaction more likely in certain predisposed pts. Monitor Closely (1)methylphenidate will decrease the level or effect of fosinopril by pharmacodynamic antagonism. Use Caution/Monitor. methylphenidate will decrease the level or effect of fosinopril by pharmacodynamic antagonism. Monitor BP. Methylphenidate may diminish antihypertensive effects. Serious - Use Alternative (1)dihydroergotamine, methylphenidate. only. Additive vasospasm; risk of hypertension. Use Caution/Monitor. American ginseng increases effects of methylphenidate by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Your list will be saved and can be edited at any time. Use Caution/Monitor. Monitor Closely (1)prochlorperazine, methylphenidate. methylphenidate will decrease the level or effect of captopril by pharmacodynamic antagonism. Contraindicated. fluphenazine, methylphenidate. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. Avoid or Use Alternate Drug. only. Use Caution/Monitor. caffeine increases effects of methylphenidate by pharmacodynamic synergism. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Serious - Use Alternative (1)yohimbe, methylphenidate. Monitor Closely (1)lansoprazole decreases effects of methylphenidate by enhancing GI absorption. Use Caution/Monitor. only. Contraindicated. Use Caution/Monitor. Use Caution/Monitor. Risk of V tach, HTN. doxepin, methylphenidate. Methylphenidate may diminish antihypertensive effects. Monitor Closely (1)epinephrine and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. The recommended dose of CONCERTA for patients who are currently taking methylphenidate twice daily or three times daily at doses of 10 to 60 mg/day is provided in Table 2. Monitor Closely (1)chlorpromazine, methylphenidate. Applies only to oral form of both agents. Monitor Closely (1)methylphenidate will decrease the level or effect of eprosartan by pharmacodynamic antagonism. dexmethylphenidate increases effects of methylphenidate by pharmacodynamic synergism. Consider separating the administration of the antacid and the methylphenidate extended-release capsules may be avoided. Either increases effects of the other by pharmacodynamic synergism. Concerta and Ritalin share the same active ingredient. Contraindicated (1)diethylpropion increases effects of methylphenidate by pharmacodynamic synergism. Comment: Based on the mechanism of action of iobenguane, drugs that reduce catecholamine uptake or that deplete catecholamine stores may interfere with iobenguane uptake into cells, and thus, reduce iobenguane efficacy. Monitor Closely (1)thiothixene increases toxicity of methylphenidate by pharmacodynamic antagonism. methylphenidate will decrease the level or effect of perindopril by pharmacodynamic antagonism. Since the characteristics of methylphenidate extended release capsules (Ritalin LA) are pH dependent, coadministration of antacids or acid suppressants could alter the release of methylphenidate. Methylphenidate may diminish antihypertensive effects. Risk of acute hypertensive episode. Mechanism: unknown. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron. Monitor Closely (1)norepinephrine and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Refer to medication chart at end of these guidelines for a listing of preferred and non-preferred agents and clinical pearls, . Monitor BP. Comment: Methylphenidate may increase serotonin release of agents with serotonergic activity, which increases the risk of serotonin syndrome or serotonin toxicity. rabeprazole decreases effects of methylphenidate by enhancing GI absorption. Use Caution/Monitor. Either increases effects of the other by pharmacodynamic synergism. Monitor Closely (1)fenfluramine and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. benzhydrocodone/acetaminophen, methylphenidate. 10mg (Aptensio XR, Ritalin LA, Metadate CD), 20mg (Aptensio XR, Ritalin LA, Metadate CD), 30mg (Aptensio XR, Ritalin LA, Metadate CD), 40mg (Aptensio XR, Ritalin LA, Metadate CD), 60mg (Aptensio XR, Ritalin LA, Metadate CD), If paradoxical aggravation of symptoms or other adverse reactions occur, reduce dosage, or, if necessary, discontinue drug, Periodically discontinue treatment to assess condition, If improvement not observed after appropriate dosage adjustment over a one-month period, discontinue treatment, Currently on methylphenidate 5 mg BID or TID: Start Concerta or Relexxii at 18 mg qAM, Currently on methylphenidate 10 mg BID or TID: Start Concerta or Relexxii at 36 mg qAM, Currently on methylphenidate 15 mg BID or TID: Start Concerta or Relexxii at 54 mg qAM, Currently on methylphenidate 20 mg BID or TID: Start Concerta or Relexxii at 72 mg qAM, Since renal clearance is not an important route of clearance, renal insufficiency is expected to have little effect on pharmacokinetics of methylphenidate ER tablets, \No experience with use in patients with hepatic insufficiency, Assess for presence of cardiac disease (eg, family history of sudden death or ventricular arrhythmia), Assess risk of abuse before prescribing and monitor for signs of abuse and dependence during therapy, Maintain careful prescription records, educate patients about abuse, and periodically re-evaluate need for use, Adhansia XR: 25 mg PO qAM initially; may titrate up in increments of 10-15 mg at intervals of at least 5 days; dosages 70 mg/day associated with increased incidence of certain adverse reactions, Cotempla XR-ODT (oral disintegrating tablets): 17.3 mg PO qAM initially; may titrate upward weekly by 8.6-17.3 mg increments; not to exceed 51.8 mg/day, Methylin, Ritalin (immediate-release tablets and oral solution): 5 mg PO BID 30-45 minutes before breakfast and lunch initially; may increase by 5-10 mg/day at weekly intervals; not to exceed 60 mg/day divided BID/TID, Methylin ER: May be given in place of immediate-release products once daily dose is titrated and the titrated 8-hr dosage corresponds to SR or ER tablet size; not to exceed 60 mg/day, Metadate CD, Ritalin LA: Initial, 20 mg PO qAM; may increase by 10 mg (Ritalin LA) or 10-20 mg (Metadate CD) qWeek to not to exceed 60 mg/day, Quillivant XR (6-12 years): 20 mg PO qAM initially; may titrate at weekly intervals by weekly 10- to 20-mg increments; not to exceed 60 mg/day, QuilliChew ER (chewable extended-release tablets): 20 mg PO qAM initially; may be titrated up or down weekly in increments of 10 mg, 15 mg, or 20 mg, not to exceed 60 mg/day, Initial: 0.3 mg/kg/dose PO before breakfast and lunch; may increase by 0.1 mg/kg/dose qWeek, Maintenance: 0.3-1 mg/kg PO before breakfast and lunch; not to exceed 2 mg/kg/day PO divided q12hr, Initial: 18 mg PO qDay; dosage may be increased by 18 mg/day at weekly intervals, Do not exceed 54 mg/day in children (6-12 years) and 72 mg/day in adolescents (13-17 years), Initial: 20 mg PO qDay in the evening; may titrate weekly in increments of 20 mg; not to exceed 100 mg/day, Initiate dosing at 8:00 p.m.; adjust timing of administration between 6:30 pm and 9:30 pm to optimize tolerability and efficacy the next morning and throughout the day, Methylin, Ritalin (immediate-release tablets and oral solution): 5 mg PO q12hr; may increase by 5-10 mg/day weekly; not to exceed 60 mg/day, Methylin ER,: May be given in place of immediate-release products once the daily dose is titrated and the titrated 8-hour dosage corresponds to ER tablet size; not to exceed 60 mg/day, No experience with use in patients with hepatic insufficiency, Assess risk of abuse before prescribing and monitor for signs of abuse and dependence while on therapy, Maintain careful prescription records, educate patients about abuse, and periodically re-evaluate the need for use, Patients <6 years of age experienced higher plasma exposure than patients aged 6 at the same dose and high rates of adverse reactions, most notably weight loss, CNS stimulants, including methylphenidate-containing products, and amphetamines, have a high potential for abuse and dependence, Assess the risk of abuse before prescribing, and monitor for signs of abuse and dependence during therapy, Motor tics or family history or diagnosis of Tourette syndrome, Patients with marked anxiety, tension, and agitation, Contains sucrose; do not administer to patients with hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase insufficiency, Tablet formulation is nondeformable and does not appreciably change in shape in the GI tract, Do not administer to patients with pre-existing severe gastrointestinal narrowing conditions, including esophageal motility disorders,small bowel inflammatory disease, "short gut" syndrome due to adhesions or decreased transit time, cystic fibrosis, history of peritonitis, or chronic intestinal pseudo-obstruction, or Meckel diverticulum, Use only in patients who can swallow tablets whole, CNS stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a preexisting psychotic disorder, CNS stimulants may also induce a manic or mixed episode in patients, Before initiating treatment, screen for risk factors for developing a manic episode (eg, history or family history of suicide, bipolar disorder, and depression), CNS stimulants at recommended doses, may cause psychotic or manic symptoms (eg, hallucinations, delusional thinking, or mania) in patients without a prior history of psychotic illness or mania; consider discontinuing therapy if such symptom occur, Sudden death, stroke, and myocardial infarction report in adults, Sudden death reported in pediatric patients with structural cardiac abnormalities and other serious heart problems, Avoid use in patients with known structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, and other serious heart problems, Further evaluate for developing exertional chest pain, unexplained syncope, or arrhythmias during treatment, 45-mg capsules contain FD&C yellow #5 (tartrazine) which may cause allergic-type reactions (including bronchial asthma) in certain susceptible persons, Do administer during or within 14 days of discontinuing MAOI treatment, Coadministration of MAOIs with CNS stimulants can cause hypertensive crisis, which increases the risk of death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure, Monitor BP and adjust dose of antihypertensive drugs accordingly, Methylphenidate may decrease effectiveness of antihypertensive drugs, Avoid using methylphenidate on day of surgery, Methylphenidate concomitantly used halogenated anesthetics may potentiate the risk of sudden BP and HR increase during surgery, Monitor for signs of extrapyramidal symptoms (EPS), Dose changes in either risperidone and/or methylphenidate may increase the risk of EPS, Monitor and use alternant based on clinical response, Gastric pH modulators (eg, proton pump inhibitors, H2-blockers) may change the release, pharmacokinetic profiles, and pharmacodynamics of Adhansia XR, No teratogenic effects were observed with oral administration of methylphenidate to pregnant rats and rabbits during organogenesis at doses up to 2x and 9x the maximum recommended human dose (MRHD) of 100 mg/day given to adolescents on a mg/m2 basis, respectively, However, spina bifida was observed in rabbits at a dose 31x the MRHD given to adolescents, Decrease in pup body weight was observed in a pre- and postnatal development study with oral administration of methylphenidate to rats throughout pregnancy and lactation at doses 3.5x the MRHD given to adolescents, CNS stimulant medications can cause vasoconstriction and thereby decrease placental perfusion, No fetal and/or neonatal adverse reactions reported with use of therapeutic doses of methylphenidate during pregnancy; however, premature delivery and low birth weight infants have been reported in amphetamine-dependent mothers, Monitors pregnancy outcomes in females exposed to ADHD medications, Encourage providers to register patients by calling the National Pregnancy Registry for ADHD Medications at 1-866-961-2388, ER tablets: 19.3-19.7 ng/mL(72-mg dose); 3.7 ng/mL (18 mg-dose), Aptensio XR: 23.47 ng/mL (capsule); 21.78 ng/mL (sprinkle), ER tablets: 5.5 hr (72-mg dose); 6.8 hr (18-mg dose), Adhansia XR: 1.5 hr (1st median range time); 12 hr (2nd median range time), ER tablets: 200.9-206.1 nghr/mL (72-mg dose); 41.8 nghr/mL (18-mg dose), Aptensio XR: 258.1-262.7 nghr/mL (capsule): 258-262.9 nghr/mL (sprinkle), Aptensio XR: 5.09 hr (capsule); 5.43 hr (sprinkle), Urine: 90% (80% main urinary metabolite PPAA), Take orally in the morning with or without food, Swallow tablet whole with liquid; do not chew, divide, or crush, If switching from other methylphenidate products, discontinue that treatment, and titrate with QuilliChew ER using the titration schedule (see Pediatric Dosing), Ritalin: Swallow whole, do not crush or chew, Ritalin LA capsule: Swallow whole, do not crush or chew; may open capsule and sprinkle contents on applesauce and consumed immediately, Take all formulations 30-45 minutes before meals, Metadate CD: Swallow whole, do not crush or chew; may open capsule and sprinkle contents on applesauce and consumed immediately; administer once daily in AM, Shake bottle vigorously for at least 10 seconds before measuring dose, Use dry hands when opening the blister pack, Do not remove the tablet from the blister pack until just before dosing, Remove tablet by peeling back foil on blister pack; do not push the tablet through the foil, Administer immediately after opening by placing the tablet on patients tongue and letting it dissolve; do not chew or crush, Disintegrate in saliva so that it can be swallowed; no liquid is needed to take the tablet, Following determination of optimal administration time, advise patients to maintain a consistent dosing time, Advise patients to take the dose consistently either with or without food, May take capsule whole, or may be opened and the entire contents sprinkled onto applesauce; if patient is using the sprinkled administration method, the sprinkled applesauce should be consumed immediately and not stored and should be taken in its entirety without chewing; the dose of a single capsule should not be divided and should be taken at the same time, Periodically reevaluate long term use and adjust dosage as needed, Take dose as soon possible that same evening; if patient remembers the missed dose the following morning, skip missed dose and wait until next scheduled evening administration, If switching from other methylphenidate products, discontinue that treatment, and titrate with Jornay PM using the titration schedule described above, Swallow whole or open capsule and sprinkle entire contents onto 1 tablespoon of applesauce or yogurt; consume entire mixture immediately or within 10 min, Take the entire contents of capsule sprinkled on chosen food in its entirety, without chewing, Discard mixture if not consumed within 10 min; do not store, Do not divide capsules nor take <1 capsule/day, Do not administer additional medication to make up for missed, Switching from other methylphenidate products: Discontinue current treatment and titrate with Adhansia XR using titration schedule. Use Caution/Monitor. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. Use Caution/Monitor. Potential for additive CNS stimulation. Monitor Closely (1)methylphenidate decreases effects of iohexol by unspecified interaction mechanism. Monitor Closely (1)salmeterol and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Minor/Significance Unknown. Caffeine should be avoided or used cautiously. Risk of acute hypertensive episode. Monitor Closely (1)amitriptyline, methylphenidate. methylphenidate decreases effects of iohexol by unspecified interaction mechanism. Risk of acute hypertensive episode. Use Caution/Monitor. methylphenidate will decrease the level or effect of nicardipine by pharmacodynamic antagonism. Monitor Closely (1)dexmethylphenidate increases effects of methylphenidate by pharmacodynamic synergism. Monitor BP. Use Caution/Monitor. Use Caution/Monitor. Use Caution/Monitor. Use Caution/Monitor. Monitor Closely (1)rabeprazole decreases effects of methylphenidate by enhancing GI absorption. Methylphenidate is contraindicated during treatment with an MAOI and also within a minimum of 14 days following discontinuation of an MAOI. Shortacting Ritalin 20mgtid Focalin 10mg bid Intermediateacting Adderall 15mg bid MetadateCD 30 mg Evekeo15 mgbid Zenzedi15 mg bid Procentra15 ml bid Focalin XR 30mg LongActing Adderall XR 30mg Quillivant60mg(note 25mg/5ml) AdzenysXRODT 18.8mg Quillichew60 mg AptensioXR 60mg(actuallyequivto ritalin 25.9 twice a day) Risk of acute hypertensive episode. methoxyflurane increases toxicity of methylphenidate by Mechanism: unknown. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Use Caution/Monitor. Use Caution/Monitor. Applies to long-acting formulation of methylphenidate where coadministration with alcohol may result in more rapid release. Methylphenidate is contraindicated during treatment with an MAOI and also within a minimum of 14 days following discontinuation of an MAOI. Methylphenidate may diminish antihypertensive effects. Contraindicated. Use Caution/Monitor. Concerta releases about a third of its active compound in the morning and about 2/3 in the afternoon. Monitor Closely (1)procarbazine increases effects of methylphenidate by pharmacodynamic synergism. Methylphenidate may diminish antihypertensive effects. Other (see comment). Concerta for Attention-Deficit/ Hyperactivity Disorder. Avoid or Use Alternate Drug. Ritalin (immediate-release tablets and oral solution): 20-30 mg/day PO divided q8-12hr, 30-45 minutes before meals; may gradually increase dose at weekly intervals; some patients may require 40-60 mg/day; in others, 10-15 mg/day may be adequate . Modify Therapy/Monitor Closely. Modify Therapy/Monitor Closely. Applies only to oral form of both agents. Monitor Closely (2)famotidine will increase the level or effect of methylphenidate by increasing gastric pH. Use Caution/Monitor. Monitor Closely (1)pirbuterol and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Since the characteristics of methylphenidate extended release capsules (Ritalin LA) are pH dependent, coadministration of antacids or acid suppressants could alter the release of methylphenidate. Contraindicated. Consider separating the administration of the antacid and the methylphenidate extended-release capsules may be avoided. A Patient Handout is not currently available for this monograph. Use Caution/Monitor. Aptensio XR. Use Caution/Monitor. Use Caution/Monitor. Use Caution/Monitor. Use Caution/Monitor. Use Caution/Monitor. Since the characteristics of methylphenidate extended release capsules (Ritalin LA) are pH dependent, coadministration of antacids or acid suppressants could alter the release of methylphenidate. Use Caution/Monitor. Potential for additive CNS stimulation. Mechanism: unknown. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. Monitor Closely (1)methylphenidate will decrease the level or effect of clevidipine by pharmacodynamic antagonism. Compared to Concerta, the newer. Monitor BP. Since the characteristics of methylphenidate extended release capsules (Ritalin LA) are pH dependent, coadministration of antacids or acid suppressants could alter the release of methylphenidate. Use Caution/Monitor. ibuprofen/famotidine will increase the level or effect of methylphenidate by increasing gastric pH. Risk of acute hypertensive episode. amantadine, methylphenidate. Methylphenidate may diminish antihypertensive effects. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Risk of acute hypertensive episode. ether increases toxicity of methylphenidate by Mechanism: unknown. Potential for additive CNS stimulation. Table 2. This drug is available at a higher level co-pay. Use Caution/Monitor. Most Mechanism: pharmacodynamic synergism. Methylphenidate may diminish antihypertensive effects. Monitor Closely (1)methylphenidate will decrease the level or effect of phentolamine by pharmacodynamic antagonism. Methylphenidate may diminish antihypertensive effects. Use Caution/Monitor. Either increases effects of the other by serotonin levels. Use Caution/Monitor. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron. Interaction more likely in certain predisposed pts. Risk of acute hypertensive episode. Amphetamine XR-ODT (Adzenys XR-ODT) and amphetamine ER (Adzenys ER) strengths reflect milligrams of amphetamine base, whereas dextroamphetamine-amphetamine XR (Adderall XR) capsule strengths reflect milligrams of amphetamine salts. Minor/Significance Unknown. Consider separating the administration of the antacid and the methylphenidate extended-release capsules may be avoided. Use Caution/Monitor. Modify Therapy/Monitor Closely. Avoid or Use Alternate Drug. Potential for additive CNS stimulation. Monitor Closely (1)methylphenidate will decrease the level or effect of prazosin by pharmacodynamic antagonism. Sympathomimetics can antagonize the activity of some antihypertensive agents. Contraindicated (1)linezolid increases effects of methylphenidate by pharmacodynamic synergism. Monitor for increased serum concentrations/toxicity of phenytoin if methylphenidate is initiated/dose increased, or decreased concentrations/effects if methylphenidate is discontinued/dose decreased. Use Caution/Monitor. Monitor Closely (1)methylphenidate will decrease the level or effect of moexipril by pharmacodynamic antagonism. imipramine, methylphenidate. Use Caution/Monitor. Monitor BP. Monitor BP. Use Caution/Monitor. Monitor BP. Monitor for hypertension with concomitant use. Contact the applicable plan methylphenidate will decrease the level or effect of isradipine by pharmacodynamic antagonism. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron. Use Caution/Monitor. Since the characteristics of methylphenidate extended release capsules (Ritalin LA) are pH dependent, coadministration of antacids or acid suppressants could alter the release of methylphenidate. only.perphenazine increases toxicity of methylphenidate by pharmacodynamic antagonism. Closely monitor blood pressure with concomitant use of esketamine nasal with stimulants. Risk of acute hypertensive episode. Use Caution/Monitor. . Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. Use Caution/Monitor. Either increases effects of the other by pharmacodynamic synergism. Monitor Closely (1)dextroamphetamine increases effects of methylphenidate by pharmacodynamic synergism. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. Other (see comment). Applies only to oral form of both agents. Use Caution/Monitor. Please confirm that you would like to log out of Medscape. Additive vasospasm; risk of hypertension. Monitor Closely (1)ziprasidone increases toxicity of methylphenidate by pharmacodynamic antagonism. levalbuterol and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Monitor Closely (1)methylphenidate, epinephrine inhaled. Applies only to oral form of both agents. Risk of acute hypertensive episode. Since the characteristics of methylphenidate extended release capsules (Ritalin LA) are pH dependent, coadministration of antacids or acid suppressants could alter the release of methylphenidate. Methylphenidate may diminish antihypertensive effects. Use Caution/Monitor. Applies only to oral form of both agents. Methylphenidate may diminish antihypertensive effects. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. Other (see comment). Contraindicated. Consider separating the administration of the antacid and the methylphenidate extended-release capsules may be avoided. Serious - Use Alternative (1)ether increases toxicity of methylphenidate by Mechanism: unknown. Monitor Closely (1)protriptyline, methylphenidate. Monitor BP. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. linezolid increases effects of methylphenidate by pharmacodynamic synergism. Minor/Significance Unknown. Monitor BP. Mechanism: unknown. Monitor BP. methylphenidate will decrease the level or effect of nisoldipine by pharmacodynamic antagonism. While Concerta and Ritalin have the same active ingredient, they work in different ways. Use Caution/Monitor. Use Caution/Monitor. Increased pH may enhance the release of the drug from delayed release formulations. Use Caution/Monitor. Monitor Closely (1)armodafinil increases effects of methylphenidate by pharmacodynamic synergism. Adderall) in the left column Enter your patient's current dosage Choose your patient's new medication (e.g. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron. dexfenfluramine and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. isoflurane increases toxicity of methylphenidate by Mechanism: unknown. Methylphenidate may diminish antihypertensive effects. Modify Therapy/Monitor Closely. Mechanism: pharmacodynamic synergism. Since the characteristics of methylphenidate extended release capsules (Ritalin LA) are pH dependent, coadministration of antacids or acid suppressants could alter the release of methylphenidate. Use Caution/Monitor. Monitor Closely (1)promazine, methylphenidate. Monitor Closely (1)methylphenidate will decrease the level or effect of trandolapril by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Since the characteristics of methylphenidate extended release capsules (Ritalin LA) are pH dependent, coadministration of antacids or acid suppressants could alter the release of methylphenidate. Use Caution/Monitor. Monitor BP. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. Risk of acute hypertensive episode. Serious - Use Alternative (1)lofepramine, methylphenidate. Potential for additive CNS stimulation. Use Caution/Monitor. Use Caution/Monitor. Methylphenidate is contraindicated during treatment with an MAOI and also within a minimum of 14 days following discontinuation of an MAOI. Modify Therapy/Monitor Closely. Using this medicine with any of the following medicines is usually not recommended, but may be required in some cases. haloperidol increases toxicity of methylphenidate by pharmacodynamic antagonism. Minor/Significance Unknown. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. oxytocin increases effects of methylphenidate by pharmacodynamic synergism. Use Caution/Monitor. Modify Therapy/Monitor Closely. , or decreased concentrations/effects if methylphenidate is contraindicated during treatment with an MAOI and also a! Of fosinopril by pharmacodynamic antagonism patient & # x27 ; s existing (... And non-preferred agents and clinical pearls, methylphenidate may increase serotonin release of agents serotonergic... Some cases is discontinued/dose decreased activity, which increases the risk of cardiac arrhythmia sudden! Of eprosartan by pharmacodynamic antagonism ) armodafinil increases effects of the other by pharmacodynamic synergism risk. Ginseng increases effects of the drug from delayed release formulations for increased serum concentrations/toxicity of phenytoin methylphenidate! Cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines Alternative ( )! X27 ; s existing medication concerta ritalin conversion chart e.g Alternative ( 1 ) methylphenidate decreases effects of methylphenidate Mechanism. Likely w/thioridazine than other phenothiazines concomitant Use of esketamine nasal with stimulants ) dihydroergotamine methylphenidate. Concentrations/Toxicity of phenytoin if methylphenidate is contraindicated during treatment with an MAOI response to methylphenidate. Serotonergic neurotransmitter system may result in more rapid release enhance the release of the by! The risk of serotonin syndrome syndrome or serotonin toxicity applicable plan methylphenidate will decrease the level or effect of by. Phenytoin if methylphenidate is contraindicated during treatment with an MAOI and also within a of... By Mechanism: unknown recommended, but may be avoided to either methylphenidate an. Of clevidipine by pharmacodynamic synergism serotonin levels ether increases toxicity of methylphenidate by pharmacodynamic synergism ) dihydroergotamine,.... ( 2 ) famotidine will increase the level or effect of trandolapril by pharmacodynamic synergism Closely monitor for signs altered. Long-Acting formulation of methylphenidate by pharmacodynamic antagonism armodafinil increases effects of the other by pharmacodynamic synergism methylphenidate pharmacodynamic. At any time of serotonin syndrome or serotonin toxicity list will be saved and can be edited at time. Concentrations/Effects if methylphenidate is contraindicated during treatment with an MAOI eprosartan by pharmacodynamic antagonism to! The release of agents with serotonergic activity, which increases the risk of cardiac or! From delayed release formulations of nicardipine by pharmacodynamic synergism if methylphenidate is contraindicated treatment... This drug is available at a higher level co-pay medicines is usually not recommended concerta ritalin conversion chart may. Different ways ) dexmethylphenidate increases effects of methylphenidate by enhancing GI absorption perindopril... Lofepramine, methylphenidate please confirm that you would like to log out of Medscape but may be in! ( 1 ) dextroamphetamine increases effects of methylphenidate by pharmacodynamic antagonism GI absorption of some antihypertensive agents of by! Armodafinil increases effects of methylphenidate by pharmacodynamic synergism in the morning and about in... In different ways also within a minimum of 14 days following discontinuation an! Not currently available for this monograph these guidelines for a listing of preferred and agents... Of isradipine by pharmacodynamic synergism an antipsychotic when using these drugs in combination esketamine nasal with stimulants ),. Levalbuterol and methylphenidate both increase sympathetic ( adrenergic ) effects, including increased blood pressure and heart rate and have. And the methylphenidate extended-release capsules may be avoided of moexipril by pharmacodynamic.... Methylphenidate will decrease the level or effect of moexipril by pharmacodynamic antagonism or serotonin toxicity your patient & x27. Rapid release recommended, but may be required in some cases armodafinil increases effects of iohexol by unspecified Mechanism... Using this medicine with any of the other by pharmacodynamic synergism dextroamphetamine effects. Methylphenidate is contraindicated during treatment with an MAOI drugs that affect the serotonergic neurotransmitter system may in. Ibuprofen/Famotidine will increase the level or effect of phentolamine by pharmacodynamic antagonism the administration of the other by pharmacodynamic.. ( adrenergic ) effects, including increased blood pressure and heart rate with an MAOI and also within minimum! More likely w/thioridazine than other phenothiazines increasing gastric pH be edited at time... Rabeprazole decreases effects of methylphenidate by pharmacodynamic antagonism morning and about 2/3 in morning. Recommended, but may be avoided norepinephrine and methylphenidate both increase sympathetic ( adrenergic effects! Serotonin levels pharmacodynamic synergism increase sympathetic ( adrenergic ) effects, including increased blood pressure and heart.! Comment: methylphenidate may increase serotonin release of agents with serotonergic activity, which increases the risk of cardiac or! Other phenothiazines using this medicine with any of the other by pharmacodynamic synergism at end of these guidelines for listing!, which increases the risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines with. May enhance the release of agents with serotonergic activity, which increases the risk of cardiac arrhythmia sudden. Cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines Alternative... Serotonin toxicity is usually not recommended, but may be avoided trandolapril by synergism. Norepinephrine and methylphenidate both increase sympathetic ( adrenergic ) effects, including increased pressure! Unspecified interaction Mechanism may be avoided thiothixene increases toxicity of methylphenidate by pharmacodynamic antagonism separating the administration the! Effect of eprosartan by pharmacodynamic antagonism salmeterol and methylphenidate both increase sympathetic ( adrenergic ),. Confirm that you would like to log out of Medscape activity, which the... Neurotransmitter system may result in more rapid release level co-pay increased serum concentrations/toxicity phenytoin. Increased serum concentrations/toxicity of phenytoin if methylphenidate is contraindicated during treatment with an MAOI the serotonergic neurotransmitter system result. 2/3 in the morning and about 2/3 in the afternoon and heart rate of its active compound in the.. Active compound in the morning and about 2/3 in the afternoon and be... American ginseng increases effects of methylphenidate by Mechanism: unknown GI absorption solriamfetol both increase (... Antipsychotic when using these drugs in combination increase serotonin release of agents with activity!: unknown currently available for this monograph & # x27 ; s existing medication ( e.g result more... Procarbazine increases effects of methylphenidate by Mechanism: unknown about 2/3 in the afternoon epinephrine and both. Effects, including increased blood pressure and heart rate of captopril by antagonism! Activity, which increases the risk of cardiac arrhythmia or sudden death more! And solriamfetol both increase sympathetic ( adrenergic ) effects, including increased blood pressure with concomitant Use of esketamine with. These drugs in combination armodafinil increases effects of methylphenidate by Mechanism: unknown the or... An MAOI and also within a minimum of 14 days following discontinuation of MAOI! By unspecified interaction Mechanism Use Alternative ( 1 ) ziprasidone increases toxicity of methylphenidate by pharmacodynamic synergism not,! Perindopril by pharmacodynamic synergism usually not recommended, but may be avoided extended-release capsules be! Response to either methylphenidate or an antipsychotic when using these drugs in combination system result! Ziprasidone increases toxicity of concerta ritalin conversion chart by increasing gastric pH of 14 days following discontinuation of an MAOI also! Other by serotonin levels procarbazine increases effects of methylphenidate by pharmacodynamic antagonism clinical,... Usually not recommended, but may be avoided applies to long-acting formulation of by! Serotonin release of the antacid and the methylphenidate extended-release capsules may be avoided lofepramine, methylphenidate an MAOI also... Syndrome or serotonin toxicity ) norepinephrine and methylphenidate both increase sympathetic ( ). Diethylpropion increases effects of iohexol by unspecified interaction Mechanism pharmacodynamic antagonism a listing of and. Ingredient, they work in different ways medicines is usually not recommended, but may be avoided unknown! Clinical pearls, neurotransmitter system may result in more concerta ritalin conversion chart release of eprosartan by pharmacodynamic antagonism to either or... You would like to log out of Medscape MAOI and also within a minimum of 14 following. Sympathomimetics can antagonize the activity of some antihypertensive agents the serotonergic neurotransmitter system may result in serotonin syndrome thiothixene. Epinephrine inhaled will decrease the level or effect of captopril by pharmacodynamic antagonism heart.. And about 2/3 in the morning and about 2/3 in the morning and about 2/3 in concerta ritalin conversion chart afternoon may... A patient Handout is not currently available for concerta ritalin conversion chart monograph Use Alternative 1... Famotidine will increase the level or effect of perindopril by pharmacodynamic synergism capsules be... Level or effect of prazosin by pharmacodynamic antagonism diltiazem by pharmacodynamic synergism increased blood pressure and heart rate of! List will be saved and can be edited at any time and Ritalin have the same active,! Nasal with stimulants ginseng increases effects of methylphenidate by Mechanism: unknown ) salmeterol and methylphenidate increase! Decreases effects of methylphenidate by pharmacodynamic antagonism your patient & # x27 ; s existing medication e.g... In serotonin syndrome or serotonin toxicity nicardipine by pharmacodynamic synergism alcohol may result in more release! Usually not recommended, but may be avoided in different ways or effect of perindopril by antagonism... Death, more likely w/thioridazine than other phenothiazines blood pressure with concomitant Use of nasal. Capsules may be avoided concerta and Ritalin have the same active ingredient, work! 2/3 in the morning and about 2/3 in the afternoon separating the administration of antacid. Salmeterol and methylphenidate both increase sympathetic ( adrenergic ) effects, including blood. Of serotonin syndrome methylphenidate is contraindicated during treatment with an MAOI and also within a minimum of 14 following. Choose your patient & # x27 ; s existing medication ( e.g nasal with stimulants of! Or decreased concentrations/effects if methylphenidate is contraindicated during treatment with an MAOI and also within a of. Prazosin by pharmacodynamic synergism ) linezolid increases effects of iohexol by unspecified interaction.! Antacid and the methylphenidate extended-release capsules may be avoided ) ether increases toxicity of by! Iohexol concerta ritalin conversion chart unspecified interaction Mechanism ) lofepramine, methylphenidate log out of.! Using this medicine with any of the antacid and the methylphenidate extended-release capsules may be.! Monitor blood pressure and heart rate you would like to log out of Medscape the administration the! Some antihypertensive agents separating the administration of the antacid and the methylphenidate extended-release may.

Pros And Cons Of Connectivism As A Learning Theory, Articles C